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Abstract. Antineoplastons are naturally occurring peptides 
and amino acid derivatives found in human blood and urine. 
Antineoplastons have been shown to control neoplastic 
growth. In the present study, we investigated demethylation 
effect of the antineoplaston AS2-1 (a mixture of phenyl-
acetylglutamine and phenylacetate in the ratio of 1:4) on 
various genes in colon cancer cells. An HpaII-MspI meth-
ylation microarray was used to investigate the methylation 
status of 51 genes at the promoter region in HCT116 and 
KM12SM human colon cancer cells before and after treat-
ment of AS2-1. The expression of protein and mRNA of the 
demethylated genes by AS2-1 in HCT116 cells was evalu-
ated. In 19 of the 34 methylated genes in HCT116 and in 7 of 
the 8 methylated genes in KM12SM, the methylation status 
was downregulated after treatment with 2 mg/ml of AS2-1 
for 24 h. AS2-1 dramatically downregulated the methylation 
status of p15 and ESR1 in HCT116 cells and of MTHFR and 
MUC2 in KM12SM cells. Both mRNA and protein expres-
sion of p15 increased in a dose- and time-dependent manner 
after treatment with AS2-1. The antineoplaston AS2-1 may 
normalize the hypermethylation status at the promoter region 
in various genes including tumor suppressor genes, resulting 
in activation of the transcription and translation in colon 
cancer.
Introduction
Antineoplasons are naturally-occurring peptides and 
amino acid derivatives found in human blood and urine, 
first described by Burzynski in 1976 (1). Antineoplaston 
A10 (3-phenylacethyl-amino-2,6-piperidinedione) is the 
first chemically-identified antineoplaston and it is partially 
hydrolyzed in pancreatic juice to phenylacetylglutamine (PG) 
and phenylacethyl isoglutamine (isoPG) when administered 
perorally. PG and isoPG are further metabolized to phenyl-
acetate (PN). The mixture of PG and PN in the ratio of 1:4 
has been formulated as antineoplaston AS2-1. Antineoplastons 
have been found to control neoplastic growth. The animal 
experiment and phase I clinical toxicological studies (2) have 
demonstrated minimal adverse effects of these agents. Thus, it 
is postulated that combining these antineoplastons with inten-
sive chemotherapy may increase antitumor efficacy without an 
increase of adverse effects in cancer patients. Clinical studies 
have described the antitumor efficacy of antineoplastons for 
various tumors including hepatocellular carcinoma, colon 
cancer and glioma (3-5).
Sodium phenylbutyrate (PB) and PN (a metabolite of PB) 
that is the active ingredient of antineoplaston AS2-1 induce 
cytostasis, differentiation and apoptosis by several cellular 
mechanisms, in glioma, neuroblastoma, leukemia cells and 
adenocarcimoma cells of the breast, colon and lung (6-9). 
PN activates the p53 and p21 genes through inhibition of 
methyltransferase and fernesylation of the RAS protein (10). 
PB activates tumor suppressor genes through inhibition 
of histone deacetylation (11,12). PG that is also the active 
ingredient of antineoplaston AS2-1 normalizes the pattern of 
genome-wide methylation, stabilizing the genes, decreasing 
expression of oncogenes such as AKT-2 and c-myc (MYCC) 
and activating tumor suppressors proteins phosphatase and 
tensin homologue (PTEN) and integrase interactor 1 (INI1) 
and promotes apoptosis (13). Thus, one of the mechanisms 
underlying the antitumor effect of antineoplaston AS2-1 is 
considered to involve regulation of tumor suppressor gene 
expression through demethylation of their promoter sequences 
and modification (acetylation) of histones.
Epigenetic alterations of gene function are now well 
known to contribute to the tumorigenesis and cancer 
progression. Specifically, abnormal promoter region meth-
ylation which typically occurs at CpG islands in known 
or candidate tumor suppressor genes contributes to tightly 
heritable gene silencing and can thereby cause the loss of 
gene function. Silencing of genes is a complex process, 
which involves methylation of DNA, histone modification 
and chromatin remodeling. Two biochemical processes play 
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a very important part in silencing of the genes: deacetylation 
of histones and methylation of DNA (14,15). Additional new 
mechanisms of methylation have been proposed explaining 
two different issues of DNA methylation in cancer progres-
sion: i) site-specific hypermethylation of promoter sequences; 
and ii) genome-wide hypo-methylation is inducing genomic 
instability, amplification of oncogenes and silencing of 
tumor suppressor genes through RNAi mechanism (16,17). 
Methylation of specific genes or methylation patterns of 
groups of genes were also found to be associated with 
responses to chemotherapeutics and prognosis.
The antitumor mechanisms on the epigenetic modification 
of antineoplastons have not yet been clarified. In the present 
study, we have investigated the epigenetic modification, in 
particular in demethylation effect of the antineoplaston 
AS2-1 and clarify sequential increase of transcription and 
translation to protein for targeting genes in colon cancer cell 
lines.
Materials and methods
Antineoplaston AS2-1. Antineoplaston AS2-1 injected formu-
lation (20 g/250 ml) which is a mixture of PG and PN in the 
ratio of 1:4, was a kind gift from Dr S.R Burzynski (Burzynski 
Institute, Houston, TX, USA).
Cell lines and culture. The HCT116 human colon cancer cell 
line (p53 wild) was obtained from the ATCC (Rockville, 
MD, USA). The KM12SM human colon cancer cell line (p53 
mutant) was a kind gift from Dr Motowo Nakajima (SBI 
Arapromo K.K., Tokyo, Japan). Each cell line was cultured in 
RPMI-1640 medium (Invitrogen, Tokyo, Japan) supplemented 
with 10% fetal bovine serum (FBS) at 37˚C/5% CO2 in 75-cm2 
culture dishes. The cells were trypsinized once a week with 
trypsin/EDTA (0.25%/0.02) and the medium was changed 
twice a week.
In vitro cell growth assay. The HCT116 and KM12SM 
cells were seeded at a density of 2.5x104 into a 6-well dish 
containing 4 ml RPMI-1640 medium (Invitrogen, Carlsbad, 
CA, USA) supplement with 10% FBS and incubated over-
night. The next day, AS2-1 was added to the subconfluent 
cultures at concentrations of 0.2, 0.5, 1, 2 and 5 mg/ml. 
The tumor cells were harvested before AS2-1 treatment as 
control, and after AS2-1 treatment at 24, 48 and 72 h. The 
number of viable tumor cells was determined by the trypan 
blue exclusion test.
Evaluation of methylation profiles at promoter regions by 
HELP assay (HpaII tiny fragment enrichment by ligation-
mediated PCR). HpaII-MspI methylation microarray 
(Methyl-Scan DNA chip; Genomictree Inc, Daejeon, South 
Korea) was used to investigate the methylation status of 51 
kinds of gene promoter region in HCT116 cells and KM12SM 
cells before and after treatment with 2 mg/ml of AS2-1 for 
24 h. All chemical reagents used were purchased from 
Sigma-Aldrich (Haverhill, MA, USA) unless otherwise noted. 
HpaII and MspI restriction enzymes were obtained from New 
England Biolabs (Ipswich, MA, USA). Oligonucleotides were 
synthesized by Bioneer Inc. (Daejeon, South Korea).
To avoid incomplete digestion and reduce the background 
noise signals, 200 ng of genomic DNA was digested with 
excessive units of HpaII and MspI (80 units each) for 6 h at 
37˚C with enzyme buffers recommended by the suppliers. The 
digested samples were inactivated at 65˚C for 20 min and then 
purified with GeneClean Turbo kit (Qbiogene, Irvine, CA, 
USA) according to the manufacturer's instructions. 
Multiplex PCR amplification was done with un-digested 
and HpaII-, MspI-digested DNA with primers sets to label 51 
target promoter regions. The sequences of the gene-specific 
primer sets used are shown in Table I. During the ampli-
fication step, fluorescent dyes were incorporated into the 
amplicons; Cy3-dUTP in MspI-digested targets, Cy5-dUTP 
in HpaII-digested targets and undigested samples labeled with 
Cy5-dUTP by same multiplex PCR. The amplification was 
carried out according to the general guidelines: denaturating 
at 94˚C for 5 min, followed by 30 cycles at 94˚C for 30 sec, 
at 66˚C for 45 sec, at 72˚C for 45 sec and a final extension at 
72˚C for 5 min. To assess PCR adequacy and ensure scanning, 
the human interferon-2 gene without HpaII site was used as a 
control.
After PCR amplification, all the amplicons were mixed 
and purified by using QIAquick PCR cleanup kit (Qiagen 
K.K., Tokyo, Japan). The hybridization mixture (100 µl) 
contained the amplified Cy5 and Cy3-labeled cDNA, 3.5X 
SSC, 5 µg of salmon sperm DNA and 0.2% sodium dodecyl 
sulfate. It was heated for 2 min at 95˚C and immediately 
applied onto Methyl Scan DNA chip. The arrays were 
incubated at 65˚C for 4 h in an eight-well platform hybridiza-
tion chamber (Genomictree). To determine the methylation 
pattern, the hybridized microarray was imaged by an Axon 
4000B scanner (Axon Instruments, Inc., Union City, CA, 
USA). The signal intensities were measured and analyzed by 
using GenePix Pro (version 4.0) software. If the signal inten-
sity of HpaII amplicon is 2-fold greater than that of MspI 
amplicon, the target region was considered to be methylated, 
while <2-fold was considered to be unmethylated (minus). 
Moreover, the methylated status was categorized into 3 
degrees, high priority (three plus), middle priority (two plus) 
and low priority (plus).
Real-time RT-PCR. To clarify the reinforcement of a tran-
scription activity of the methylate normalized gene by AS2-1, 
real-time RT-PCR (relative quantitative) for p15 messenger 
RNA in HCT116 cells were evaluated. The HCT116 cells were 
seeded at a density of 2.5x104/ml into a 6-well dish containing 
4 ml RPMI-1640 medium (Invitrogen) supplement with 10% 
fetal bovine serum (FBS) and incubated overnight. The next 
day, AS2-1 was added to the subconfluent cultures at concen-
trations of 0.2, 1 and 2 mg/ml. The tumor cells were harvested 
before AS2-1 treatment as control, after AS2-1 treatment at 12, 
24 and 48 h.
Isolated RNA was controlled for quality by 2% agarose 
gel separation and ethidium bromide staining. RNA was 
quantified by spectrophotometry. Complementary DNA 
(cDNA) was synthesized using 2 µg of total RNA. The 20 µl 
reverse transcription reaction consisted of 2 µl 10X RT 
buffer, 0.5 mM each dNTP, 1 µM Oligo-dT primers and 4 U 
Omniscript reverse transcriptase (Qiagen K.K). The reverse 
transcription reaction was incubated for 1 h at 37˚C and then 
ONCOLOGY REPORTS  31:  19-26,  2014 21
Table I. Primer information for HpaII-MspI-PCR assay.
Gene Forward primer (5'-3')  Reverse primer (5'-3') Amplicon size (bp)
ASIC2 ccaggaggcgaggagagaatg cctcctctcctcctcctcca 178
Apaf-1 ccttggggcttggggtgtgt cctcaagtcttcgcgggtcg 201
APC caggcaacccagacgtccagag ggaagttgatggcagttgacac 310
AR ggacccgactcgcaaactgtt gctggcgtggtgcgtccct 195
BRCA1 gcgtgagctcgctgagacttc ccttcctgatcctcagcgctt 302
hCTR ggatcagagttggaagagtccc cctcccagcgccagcgact 382
CALCR cctgtgtttacgcggcgcttt gcagcagaattgatgagagcca 229
CDH13 ccatgcaaaacgagggagcgt cgcacagaacgagcggagttc 258
CDKN2A (p16) gcagcatggagccttcggct ccaggaggaggtctgtgattac 292
CDKN2B (p15) ccttggcccagctgaaaacg gcactctctccttcctaggag 304
CFTR cctccagcgttgccaactgg cgtctgggctcaagctccta 443
COMT cccattgctctgtgcagcct ggctgggtgccttgtctaag 202
DAPK1 ccactcactccctagctgtgtt cccagttgctcgaggcactgc 224
EDN1 ggtacacaggccatataggaac ccgaatccctgggcatcagg 620
EBR ggagggaacagcggtttccaa cgtaacgggaggaatacagac 284
EPHA3 cctgtcccatgggcgacg gctggtgcagagggcagtg 295
EPO gcagcccccatgacccaca gctgttatctgcatgtgtgcgt 175
ESR cctggatccgtctttcgcgtt gcagggtgcagaccgtgtcc 510
FHIT ctccctccctctgcctttcat ggcgatcccaccctgagacc 217
H19 gccatgtgcaaagtatgtgcag cctggacagttccagcacac 228
Heparanase gggagaggaagggatgaatact ggtcacgttcacttacgaaatca 273
hMLH1 cgggcagtacctctctcagcaac ggcttgtgtgcctctgctgagg 528
HTR1B gggagcttccttggccagga ctctgccctccctctcttttc 434
IL-8 ggaagtgtgatgactcaggttt ggctcttgtcctagaagcttgt 195
JunB ggaaacgacgccaggaaagct gcagcgagcggcgagctct 174
LAMA5 ggcacaggctgactcatgtgt gcttgcaggctgaccgcct 192
LDHB gggagtgtgcacacttgagc ctaccaggagagagaaggctc 237
BLT1 gtgagcgccatcgtgcttgc caccactttcagctgagggg 332
LRP2 cgtgtgcacgtgtgagtgtg cctctgctagcgaacgctcc 485
MAGE1 gcagagagagagtcttggctttc cttgactgccgaccagtcctg 501
MDR3 cctaggagtactcacttcagg cctctgcttctttgagcttgg 230
MGMT ccgtttgcgacttggtgagt ggaaaggctgggcaacacctg 199
MTHFR gctgcctgccccctgatgc ccccaggcaccaccactcc 346
MUC2 ggttggtcctcccagcgtaa cctggcaggagggtaggag 239
PGR ggtagggaggggctttggg ccagcgagcggcaagtggg 579
PIK3CG ccctctggggcattcattacta ggaagcactacagcccttcag 139
PLS3 (TLS3) cacccagttgatgtgacaggc gctccaactgaaatttctccga 393
PTGS2 cccatccaaggcgatcagtc ggtaggctttgctgtctgagg 471
RAR-b gtgacagaagtagtaggaagtga ccaggcttgctcggccaatc 338
RB1 ggatagggatgaggcccaca cgtcccctgagaaaa accgg 341
S100A2 ccacagttctctcattccagc ctcaggattctttttgcagcaac 578
SHP1 gctctgcttctcttcccttgc gggactaagcctcagatgcag 193
SKT11 (LKB1) cgaggacgaagttgaccctg ggacccagggtcctggagt 324
NIS cccagtccagggctgaaagg ctccctgggttaggaatctatg 468
HLTF ggagacggcgtcgacgtct cgctgagtgggatgacaagag 181
SRBC gcagtggagacctgaaacagg ctggctgcactacggtcagg 286
TFF1 ctcagatccctcagccaagata cgagtcagggatgagaggcc 229
TP73 gcctttggcgccaaagacagc cgaaaccgcttagtaaccaactc 308
TUSC3 (N33) ccttcatcatccaagaaggcatt cgaggacgcagagtaggaga 295
VHL cgagttggcctagcctcgc cgtcttcttcagggccgtac 311
WT1 gctgctgagtgaatggagcg gggtgaatgagtaggtgggag 293
IFN (control) gcagctgcagcagttccaga tgctcatgagttttccctggt 221
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at 93˚C for 15 min. Real-time PCR analysis was performed 
using the ABI Prism 7700 sequence detection system (Applied 
Biosystems, Foster City, CA, USA) as previously described 
(18). Briefly, reactions were performed in a 96-well optical 
reaction plated on cDNA equivalent to 50 ng of DNase-
digested RNA in a volume of 25 µl, containing 12.5 µl of 
TaqMan Universal Master Mix and optimized concentrations 
of carboxy fluorescein (FAM)-labeled probe and forward and 
reverse primers following the manufacturer's protocol. All 
primers and FAM-labeled probes for mouse p15 (forward, 
5'-TCTGCAGCTGGATCTGGTCC-3' and reverse, 5'-TCCT 
GAAAGGTAGAGGGCCC-3') and GAPDH (forward, 5'-CA 
TCTCCTCCCGTTCTGCC-3' and reverse, 5'-GTGGTGC 
AGGATGCATTGC-3') were obtained from Applied 
Biosystems. The mRNA expression of p15 was normalized to 
the level of GAPDH mRNA. Data were processed by the RQ 
Manager 1.2 software.
Western blot analysis. The cells were cultured as previ-
ously described. The cells were directly lysed in a sample 
Figure 1. In vitro cell growth inhibition by antineoplaston AS2-1. Human colon carcinoma HCT116 and KM12SM cells were incubated as described in 
Materials and methods. Antineoplaston AS2-1 inhibited (A) HCT116 and (B) KM12SM cell growth in a time- and dose-dependent manner.
Table II. Methylation status in HCT116 cells before and after treatment with AS2-1.
Apaf-1 APC AR ASIC2 BLT1 BRCA1 CALCA
(+) ⇒ (-) (+) ⇒ (-) (+) ⇒ (-) (-) ⇒ (-) (+++) ⇒ (+++) (-) ⇒ (-) (-) ⇒ (-)
CDH13 CFTR COMT DAPK EBR EDN1 EphA3
(+) ⇒ (+) (-) ⇒ (-) (-) ⇒ (-) (+) ⇒ (+) (+) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-)
EPO ESR1 FHIT hCTR Heparanase HLTF hMLH1
(+) ⇒ (-) (++) ⇒ (-) (+) ⇒ (-) (+) ⇒ (+) (+) ⇒ (+) (-) ⇒ (-) (+) ⇒ (-)
HTR1B H19 IL-8 JunB Laminin5 LDHB LKB
(+) ⇒ (-) (+) ⇒ (+) (-) ⇒ (-) (+) ⇒ (+) (-) ⇒ (-) (+) ⇒ (-) (+) ⇒ (-)
LRP2 MAGE MDR3 MGMT MTHFR MUC2 NIS
(+) ⇒ (-) (+) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (++) ⇒ (++) (++) ⇒ (+) (+) ⇒ (+)
N33 PGR PIK3CG PTGS2 P15 P16 P73
(+) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (++) ⇒ (-) (-) ⇒ (-) (+) ⇒ (+)
RAR-β RB1 SHP1 SRBC S100A2 TFF1 TLS3
(+) ⇒ (-) (+) ⇒ (+) (+) ⇒ (-) (+) ⇒ (-) (+) ⇒ (-) (-) ⇒ (-) (+) ⇒ (+)
VHL WT1
(+) ⇒ (+) (+) ⇒ (+)
(Before treatment) ⇒ (After treatment: antineoplaston AS2-1 2 mg/ml, 24 h). If the signal intensity of HpaII amplicon is 2-fold greater 
than that of MspI amplicon, the target region was considered to be methylated, while <2-fold was considered to be unmethylated 
(minus). Moreover, the methylated status was categorized into 3 degrees, high priority (three plus), middle priority (two plus) and low 
priority (plus).
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buffer (0.5 M Tris-HCl, pH 6.8, 10% glycerol, 10% SDS, 
6% mercaptoethanol, 0.05% bromophenol blue). Protein 
(10 µg) was separated on 4% SDS-PAGE gel at 120 V for 
1.5 h. After electrophoresis, the proteins were transferred 
to a PVDF membrane (Bio-Rad Laboratories, Hercules, 
CA, USA) at 100 V for 60 min. The membrane was blocked 
in PBS containing 0.1% Tween-20 (FBS-Tween) with 5% 
skimmed milk at room temperature for 60 min, subsequently 
incubated with anti-p15 mouse monoclonal antibody (Abcam, 
Cambridge, UK) at 4˚C overnight. After washing with 
PBS-Tween, the membrane was incubated with a horseradish 
peroxidase-conjugated goat anti-rabbit IgG or anti-mouse IgG 
secondary antibody (Santa Cruz Biotechnology, Dallas, TX, 
USA). The membrane was washed with PBS-Tween, and the 
signal was detected using an ECL detection kit (Amersham 
Pharmacia Biotech Inc., Piscataway, NJ, USA). A mouse 
monoclonal antibody against β-actin (Sigma-Aldrich, St. 
Louis, MO, USA) was used to control for protein loading. 
The amount of each protein was quantified as ratio to actin. 
Quantification of band densities was performed using the 
public domain NIH Image software.
Results
Cell growth inhibition by antineoplaston AS2-1. Anti-
neoplaston AS2-1 inhibited the cell growth of KM12SM and 
HCT116 in a culture in a dosa- and time-dependent manner 
(Fig. 1). There was no difference in cell growth inhibition 
by AS2-1 between the wild p53 HCT116 and the mutant p53 
KM12SM cell lines.
Methylation status. Among the 51 genes, there were 34 
methylated genes in promoter sequence in HCT116 cells. In 
19 (56%) of the 34 methylated genes the methylation status 
was downregulated after treatment with 2 mg/ml of AS2-1 for 
24 h, in particular, the methylation status of cyclin-dependent 
kinase inhibitor p15 (INK4B) and estrogen receptor 1 (ESR1) 
in HCT116 cells were dramatically downregulated from two 
plus to minus (Tables II and III). Among the 51 genes, there 
were 8 methylated genes in KM12SM cells. In 7 (88%) of the 
8 methylated genes in KM12SM cells, the methylation status 
was downregulated after treatment with 2 mg/ml of AS2-1 
for 24 h, in particular the methylation status of methylene-
tetrahydrofolate reductase (MTHFR) and mucin2 (MUC2) 
in KM12SM cells was dramatically downregulated from 
Table III. Summary of methylation status in HCT116 cells.
Before treatment After treatment
----------------------------------- ----------------------------------
Status n Status n (%)
(-) 17 (-) 17 100
(+) 29 (+) 13 45
  (-) 16 55
(++) 4 (++) 1 25
  (+) 1 25
  (-) 2 50
(+++) 1 (+++) 1 100
Table IV. Methylation status in KM12SM cells before and after treatment with AS2-1.
Apaf-1 APC AR ASIC2 BLT1 BRCA1 CALCA
(-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (+++) ⇒ (+++) (-) ⇒ (-) (-) ⇒ (-)
CDH13 CFTR COMT DAPK EBR EDN1 EphA3
(+) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-)
EPO ESR1 FHIT hCTR Heparanase HLTF hMLH1
(-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (+) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-)
HTR1B H19 IL-8 JunB Laminin5 LDHB LKB
(-) ⇒ (-) (+) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-)
LRP2 MAGE MDR3 MGMT MTHFR MUC2 NIS
(-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (++) ⇒ (-) (++) ⇒ (-) (-) ⇒ (-)
N33 PGR PIK3CG PTGS2 P15 P16 P73
(-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-)
RAR-β RB1 SHP1 SRBC S100A2 TFF1 TLS3
(-) ⇒ (-) (+) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-) (-) ⇒ (-)
VHL  WT1
(-) ⇒ (-) (+) ⇒ (-)
(Before treatment) ⇒ (After treatment: antineoplaston AS2-1 2 mg/ml, 24 h). If the signal intensity of HpaII amplicon is 2-fold greater than that 
of MspI amplicon, the target region was considered to be methylated, while <2-fold was considered to be unmethylated (minus). Moreover, the 
methylated status was categorized into 3 degrees, high priority (three plus), middle priority (two plus) and low priority (plus).
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two plus to minus (Tables IV and V). There was no gene 
with methylation status upregulated in both HCT116 and 
KM12SM cells.
Of interest, in between the cell lines there was a difference 
in demethylation effect of AS2-1 in the 8 genes which were 
methylated in both HCT116 cells and KM12SM cells. Among 
the 8 genes, there was only one gene (MUC2) of which meth-
ylation status was downregulated after treatment with AS2-1 
in HCT116 cells, whereas in 7 of the 8 methylated genes in 
KM12SM cells, the methylation status were downregulated by 
AS2-1 (Fig. 2).
Transcription of p15 mRNA. Real-time RT-PCR analysis 
revealed that AS2-1 upregulated the expression of p15 mRNA 
in a time- and dose-dependent manner in HCT116 cells 
(Fig. 3).
Translation of p15 protein. Western blot analysis revealed that 
AS2-1 upregulated the expression of p15 protein in a time- and 
dose-dependent manner in HCT116 cells (Fig. 4).
Discussion
Burzynski found compounds in the blood and urine of healthy 
adults that were absent in blood and urine of cancer patients, 
as first described in 1976 (1). He proposed the hypothesis that 
these peptide fractions could trigger normal differentiation 
and apoptosis in neoplastic cells and their deficiency in cancer 
patients contributed to disease progression. These peptide 
fractions were termed ‘antineoplastons’.
Re-expression of abnormally silenced suppressor genes is 
being investigated for potential clinical applications. Based 
on animal experiments and human observations, the drugs 
which can restore normal gene expression in aging should 
inhibit insulin-like growth factor 1 (IGF-1)/AKT and RAS 
pathways and provide proper anticancer defense through 
normal activity of tumor suppressors p53 and p21 (19). It 
has also been introduced that a group of amino acid deriva-
Table V. Summary of methylation status in KM12SM cells.
Before treatment After treatment----------------------------------- ----------------------------------
Status n Status n (%)
(-) 43 (-) 43 100
(+) 5 (+) 0
  (-) 5 100
(++) 2 (++) 0
  (+) 0
  (-) 2 100
(+++) 1 (+++) 1 100
Figure 2. Multiple clustering analysis of methylation status. Red pixels rep-
resent methylation status: the intensities of red pixels depend on methylation 
status (priority). Greenish black pixels represent unmethylated status. Sample 
HCT116, before treatment; sample HCT116 2 mg, after treatment with 2 mg 
of antineoplaston AS2-1 for 24 h; sample KM12SM, before treatment; sample 
KM12SM 2 mg, after treatment with 2 mg of AS2-1 for 24 h
Figure 3. Real-time RT-PCR analysis for p15 mRNA in HCT116 cells. 
(A) HCT116 cells were treated with 2 mg/ml of antineoplaston AS2-1 for 12, 
24 and 48 h. (B) HCT116 cells were treated with 0.2, 1 and 2 mg/ml of AS2-1 
for 24 h. AS2-1 upregulated the expression of p15 mRNA in a time- and 
dose-dependent manner in HCT116 cells.
Figure 4. Western blot analysis for p15 protein in HCT116 cells. (A) HCT116 
cells were treated with 1 mg/ml or 2 mg/ml of antineoplaston AS2-1 for up 
to 48 h. (B) HCT116 cells were treated with 0.2, 0.5, 1 and 2 mg/ml of AS2-1 
for 12 or 24 h. AS2-1 upregulated the expression of p15 protein in a time- and 
dose-dependent manner in HCT116 cells.
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tives and organic acids activate the tumor suppressors p53, 
p21, PTEN and INI1 and decrease overexpression of RAS and 
AKT-2 and MYCC oncogenes (20).
The current theory of the mechanisms of action of anti-
neoplastons is that they function as ‘molecular switches’, 
turning on tumor suppressor genes and turning off onco-
genes. It has been suggested that AS2-1 and PN activate 
tumor suppressor genes p53 and p21 through demethylation 
of their promoter sequences (21). In the present study, the 
methylation chip analyses revealed that AS2-1 downregu-
lated methylation status at promoter sequences in various 
genes including well-known tumor suppressor genes and 
the candidates for tumor suppressor gene in both p53 wild 
HCT116 and p53 mutant KM12SM colon cancer cells. The 
results suggest that AS2-1 has a potent effect to normalize 
hypermethylation at promoter regions independently of p53 
mutation. Of interest, the demethylation effect was seen more 
completely in the KM12SM cells (8 methylated genes) than 
in the HCT116 cells (34 methylated genes). The difference in 
demethylation effect in the same genes between the two cell 
lines suggests that the demethylation effect of AS2-1 may 
depend on the cell type not on the genes. Cytidine analogs 
such as 5-azacytidine (azacitidine) and 5-azadeoxycytidine 
(decitabine) are the most commonly used demethylating 
agents. These compounds work by binding to DNA methyl-
transferases that catalyse the methylation reaction and titrate 
out DNA methyltransferases (22). If the demethylation effect 
of AS2-1 depends on activity of DNA methyltransferases, it 
is suspected that AS2-1 may demethylate at CpG islands of 
promoter region more completely in tumor cells with a low 
DNA methyltransferase activity.
One of the dramatically demethylated genes after treatment 
with AS2-1 in HCT116 cells was the tumor suppressor gene, 
cyclin-dependent kinase inhibitor p15 (INK4B). Sequentially 
the expression of p15 mRNA and p15 protein was upregulated 
by treatment with AS2-1. The results indicate that treatment 
with AS2-1 leads to re-expression of p15 mRNA and p15 
protein. This gene is localized to a region on chromosome 9p21 
frequently deleted in human tumors. p15 gene is an important 
mediator of cell cycle control, especially in pathways stimu-
lated by TGF-β (23), raising the issue of whether inactivation 
of one or both of the genes and cyclin-dependent kinase 
inhibitor p16 (INK4A) with homozygous deletion involving the 
nearby p15 is necessary, because both proteins are inhibitors 
of cyclin-dependent kinase 4 (INK4 family) (24,25) and are 
highly homologous throughout their coding sequence (26). It 
has been reported that the p15 gene is commonly inactivated in 
association with promoter region hypermethylation involving 
multiple sites in a 5'-CpG island in glioma, leukemia and 
myelodysplastic symdromes. In other tumors, including lung, 
head and neck, breast, prostate and colon cancer, inactiva-
tion of p15 occurs rarely and with concomitant inactivation 
of p16. It has been shown that aberrant methylation of p15 is 
associated with transcriptional loss of this gene and treatment 
with the demethylating agent decitabine leads to reactivation 
of p15, inducing growth arrest and apoptosis in myeloid cell 
lines (27). AS2-1 may activate silenced tumor suppressor p15 
by demethylation and sequentially upregulates the expression 
of p15 protein in colon cancer HCT116 cells.
In conclusion, antineoplaston AS2-1 may normalize 
hypermethylation status at the promoter region in various 
tumor suppressor genes of which expression is silenced in 
colon cancer. Then, AS2-1 activates the gene transcription and 
protein translation, resulting in differentiation, cell cycle arrest 
and apoptosis in cancer cells.
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